StockNews.com Initiates Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)

StockNews.com began coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research report issued to clients and investors on Monday. The firm set a “sell” rating on the stock.

Ayala Pharmaceuticals Stock Up 405.5 %

NASDAQ:ADXS opened at $0.10 on Monday. The firm has a market capitalization of $4.31 million, a PE ratio of -0.01 and a beta of 1.51. Ayala Pharmaceuticals has a 12-month low of $0.00 and a 12-month high of $1.49. The firm has a 50-day moving average price of $0.05 and a 200 day moving average price of $0.30.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.